Combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a consistent safety profile in special
Continue reading »Home »
Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Combination Approved for Previously Treated MSI-H/dMMR Metastatic Colorectal Cancer
PRINCETON, N.J.– July 11, 2018 (BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy
Continue reading »Researchers find combination can enhance ipilimumab immunotherapy
Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint
Continue reading »